Репозиторий
Гомельского государственного медицинского университета
    • русский
    • English
  • русский 
    • русский
    • English
  • Войти
Просмотр элемента 
  •   Главная
  • Публикации учёных ГомГМУ в изданиях РБ и за рубежом
  • Публикации в научных журналах
  • 2023
  • Просмотр элемента
  •   Главная
  • Публикации учёных ГомГМУ в изданиях РБ и за рубежом
  • Публикации в научных журналах
  • 2023
  • Просмотр элемента
JavaScript is disabled for your browser. Some features of this site may not work without it.

Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults

Открыть
Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults.pdf (90.09Кб)
Дата публикации
2023
Автор(ы)
Stoma, I.
Korsak, K.
Voropaev, E.
Osipkina, O.
Kovalev, A.
Метаданные
Показать полную информацию
Библиографическое описание
Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults / I. Stoma, K. Korsak, E. Voropaev [et al.] // 10th International Congress of the Asia Pacific Society of Infection Control 2022 (APSIC 2022) : abstracts, february 2023. – [Publ.] Antimicrobial Stewardship & Healthcare Epidemiology. – 2023. – Vol. 3, Iss. S1. – PP. s4.–s5.
Аннотация
Objectives: Data comparing the immunogenicity of Sputnik-V and Sinopharm vaccines in seropositive and seronegative groups are lacking. We compared the immunogenicity of Sputnik-V (Gam-COVID-Vac) and Sinopharm (BBIBP-CorV) vaccines in seronegative and seropositive groups. Methods: In total, 60 adults participated the study. The immune response after vaccination was assessed using enzyme immunoassay. IgG levels were measured in all participants at 3 time points: before vaccination, 42 days after the first vaccine dose, and 6 months after the first vaccine dose. The results of the SARS-CoV-2 antibody test were quantified according to the WHO First International Standard and expressed in international units (BAU per mL). Results: The study participants were divided into 2 groups: 30 people (50%) were vaccinated with Sputnik-V (Gam-COVID-Vac) and 30 people (50%) were vaccinated with Sinopharm (BBIBP-CorV). The groups had no difference in sex composition. The highest antibody levels were observed 42 days after vaccination in both the seronegative group (P = .006) and the seropositive group (P < .001). At 6 months after vaccination, the IgG value declined much farther among the seronegative group (P = .003) compared to those who had recovered from COVID-19 before vaccination. However, the “hybrid immunity” generated by the Sputnik-V vaccine had greater strength and duration (P < .001). Conclusions: This study showed that IgG levels in vaccinated individuals who previously recovered from SARS-CoV-2 infection (“hybrid immunity”) were higher than in SARS-CoV-2–naïve individuals. In a comparative part of the study, the Sputnik-V vaccine had greater strength and duration of immune response across the 6-month observation period (P < .001).
Ключевые слова
vaccines Gam-COVID-Vac
vaccines Sinopharm BBIBP-CorV
вакцина Gam-COVID-Vac
вакцина Sinopharm BBIBP-CorV
 
URI
http://elib.gsmu.by/handle/GomSMU/16221
DOI
https://doi.org/10.1017/ash.2023.15
Коллекции
  • 2023 [112]

Контакты | Отправить отзыв
 

 

Просмотр

Весь репозиторий: Разделы и коллекцииДата публикацииАвторыЗаглавияТемыв этой коллекцииДата публикацииАвторыЗаглавияТемы

Моя учетная запись

ВойтиРегистрация

Контакты | Отправить отзыв